Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS‐24 and SINUS‐52
International Forum of Allergy & Rhinology · 2024-03 · 14 (3) · 668-678
DOI: 10.1002/alr.23249 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Forum of Allergy & Rhinology, online erschienen am 22.08.2023. Verfasst von Claus Bachert und 11 weiteren Autor:innen. Beteiligte Einrichtung: University Hospital of Münster, Münster, Germany. Hauptthemen laut MEDLINE: Nasal Polyps, Rhinosinusitis, Rhinitis, Sinusitis. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sanofi, Regeneron Pharmaceuticals Inc. ClinicalTrials.gov identifiers.
Abstract (Originalsprache)
Background
This post hoc analysis of the international SINUS‐24/‐52 trials (NCT02912468/NCT02898454) aimed to assess dupilumab efficacy in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) according to different definitions of type 2 inflammatory signature.
Methods
Six definitions of type 2 inflammation were used: ≥150 eosinophils/μL or total immunoglobulin E (IgE) ≥100 IU/mL with a coexisting type 2 condition; ≥150 eosinophils/μL or total IgE ≥100 IU/mL; ≥150 eosinophils/μL; ≥250 eosinophils/μL or total IgE ≥100 IU/mL; coexisting asthma or ≥300 eosinophils/μL; presence of a coexisting type 2 condition. Odds ratios (ORs; dupilumab vs. placebo) for achieving clinically meaningful improvement (≥1 point) from baseline to week 24 (pooled SINUS‐24/‐52) and week 52 (SINUS‐52) were calculated for nasal polyp score (NPS; range 0–8), nasal congestion/obstruction score (NC; 0−3), and loss of smell score (LoS; 0−3).
Results
At baseline ( n = 724), most patients displayed a type 2 inflammatory signature across definitions (64.2%–95.3%). At week 24, ORs for clinically meaningful improvement ranged from 11.9 to 14.9 for NPS across type 2 definitions, 6.5–9.6 for NC, and 12.2–17.8 for LoS (all p < 0.0001). OR ranges were similar or greater at week 52: 19.0–36.6, 7.6–12.1, and 9.2–33.5, respectively (all p < 0.0001).
Conclusion
Most patients with CRSwNP in the SINUS study had type 2 inflammation. Dupilumab demonstrated robust efficacy across definitions of type 2 inflammation, consistent with its profile as an inhibitor of Interleukin‐4 and Interleukin‐13 signaling, key and central drivers of type 2 inflammation in CRSwNP. Key Points This study assessed type 2 inflammation prevalence and dupilumab efficacy in chronic rhinosinusitis with nasal polyps according to algorithm‐defined type 2 inflammation Dupilumab efficacy was similar across all type 2 definitions
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University Hospital of Münster, Münster, Germany.
- Sun Yat-sen University, The First Affiliated Hospital, Guangzhou, China.
- Karolinska Hospital, Stockholm University, Stockholm, Sweden.
- Sanofi, Chilly Mazarin, France.
- Division of Otolaryngology - Head and Neck Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Guy's and St Thomas' Hospitals, London, UK.
ORCID-Profile: Claire Hopkins
Förderung
- Sanofi
- Regeneron Pharmaceuticals Inc. ClinicalTrials.gov identifiers
Zitieren
APA
Bachert, C., Khan, A. H., Lee, S. E., Hopkins, C., Peters, A. T., Fokkens, W., Praestgaard, A., Radwan, A., Nash, S., Jacob-Nara, J. A., Deniz, Y., & Rowe, P. J. (2024). Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS‐24 and SINUS‐52. International Forum of Allergy & Rhinology, 14(3), 668-678. https://doi.org/10.1002/alr.23249
Vancouver
Bachert C, Khan AH, Lee SE, Hopkins C, Peters AT, Fokkens W, et al. Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS‐24 and SINUS‐52. International Forum of Allergy & Rhinology. 2024;14(3):668-678. doi:10.1002/alr.23249
BibTeX
@article{Bachert2024,
author = {Bachert, Claus and Khan, Asif H and Lee, Stella E and Hopkins, Claire and Peters, Anju T and Fokkens, Wytske and Praestgaard, Amy and Radwan, Amr and Nash, Scott and Jacob-Nara, Juby A and Deniz, Yamo and Rowe, Paul J},
title = {Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS‐24 and SINUS‐52},
journal = {International Forum of Allergy & Rhinology},
year = {2024},
volume = {14},
number = {3},
pages = {668--678},
doi = {10.1002/alr.23249}
}
EUVIMED